Director Robert L. Zerbe, MD, filed a Form 144 notice on November 9, 2026, disclosing a proposed sale of 2,000 shares of Vericel Corp common stock following a stock option exercise, with the sale to be executed through Fidelity Brokerage Services LLC on NASDAQ.

Key Highlights

  • Proposed sale: 2,000 shares of Vericel Corp common stock, with an aggregate market value of $115,753.49, according to the filing.
  • Acquisition method: The shares were acquired via a stock option exercise from the issuer on November 9, 2026, with payment made in cash.
  • Shares outstanding: The filing lists 51,029,770 shares of common stock outstanding at the time of filing.
  • Prior sales in past 3 months: Robert Zerbe sold 2,500 shares on November 4, 2026, for gross proceeds of $113,502.00, and 3,000 shares on November 5, 2026, for gross proceeds of $156,682.25.
  • Rule 10b5-1 plan: The filing indicates a plan adoption date of May 19, 2026, in connection with Rule 10b5-1.
  • Broker: Fidelity Brokerage Services LLC, 900 Salem Street, Smithfield, RI 02917, is named as the executing broker.

Zerbe's Proposed November 2026 Sale of Vericel Common Stock

According to the Form 144 notice filed with the U.S. Securities and Exchange Commission, Robert L. Zerbe, MD, a director of Vericel Corp (NASDAQ:VCEL), intends to sell 2,000 shares of the company's common stock. The filing lists an approximate sale date of November 9, 2026, and an aggregate market value of $115,753.49 for the proposed sale. The shares were acquired through a stock option exercise from the issuer on the same date, with payment described as cash.

The filing also discloses two prior sales by Zerbe within the past three months. On November 4, 2026, he sold 2,500 shares for gross proceeds of $113,502.00, and on November 5, 2026, he sold 3,000 shares for gross proceeds of $156,682.25. All sales are listed under the name Robert Zerbe at the company's address of 25 Blue Sky Drive, Burlington, Massachusetts 01803.

The notice states that the sale is being made in reliance on a Rule 10b5-1 trading plan adopted on May 19, 2026. The filing is signed by Jessica Spraker as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Robert Zerbe. Vericel Corp's common stock has an SEC file number of 001-35280, and the company is headquartered at 25 Blue Sky Drive, Burlington, Massachusetts 01803.

What Was Disclosed

Vericel Corp director Robert L. Zerbe, MD, filed a Form 144 notice proposing the sale of 2,000 shares of common stock valued at $115,753.49, acquired via stock option exercise, with the sale planned for November 9, 2026, through Fidelity Brokerage Services LLC under a Rule 10b5-1 plan.